BBG50 (BPC-157 + GHK-Cu + TB-500)
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
BBG50 is a research blend containing 10 mg BPC-157, 50 mg GHK-Cu and 10 mg TB-500 per vial, totaling 70 mg of labeled components. Each box contains 10 vials. BBG50 is the SKU name, not the total mass per vial. Its composition differs from GLOW50, which contains less GHK-Cu and BPC-157.
No published certificates yet.
SKU y presentación
| SKU | Por vial | Viales por caja | Precio de la caja |
|---|---|---|---|
| BBG50 | 70 mg | 10 | 128,00 US$ |
Las cantidades nominales describen la etiqueta; los resultados medidos figuran en cada informe. Un informe publicado no confirma el lote asignado a un pedido futuro.
Preguntas sobre el producto y la documentación
¿Cómo interpreto el tamaño y la cantidad?
La cantidad por vial y los viales por caja aparecen por separado. El precio corresponde a una caja. En mezclas, el tamaño puede ser combinado; consulte la etiqueta y el informe para cada componente.
¿Cómo encuentro el COA correspondiente?
Compare producto, SKU y número de lote. La página del lote muestra resultados, informe original y enlace de verificación. Consulte al soporte si su pedido no indica el lote asignado.
¿Un resultado de pureza significa que se aprobaron todas las pruebas?
No. Identidad, pureza, llenado y endotoxinas son mediciones distintas. Revise cada resultado y unidad. Un resultado ausente no equivale a aprobado, y un valor inferior a un límite no es cero.
Research Information
BBG50 brings together compounds associated with extracellular-matrix, tendon-cell and peptide-characterization research. Its verified catalog composition is BPC-157 10 mg, GHK-Cu 50 mg and TB-500 10 mg per vial. Research on individual ingredients does not establish a combined effect, and TB-500 identity should be matched to product-specific analytical documentation before selecting relevant literature.
BBG50 (BPC-157 + GHK-Cu + TB-500) Research & Studies
Per-vial composition and packaging
Each vial contains BPC-157 10 mg, GHK-Cu 50 mg and TB-500 10 mg, totaling 70 mg. Each box contains 10 vials. The label BBG50 identifies this SKU; its numerical suffix does not represent the combined mass of all three components.
GHK-Cu and matrix-associated endpoints
Primary studies of GHK-Cu examined collagen synthesis in fibroblast cultures and connective-tissue accumulation in rat experimental wounds. These findings provide context for extracellular-matrix research. They should be attributed to the tested ingredient and model rather than presented as demonstrated properties of BBG50.
BPC-157 and preclinical tendon research
BPC-157 has been investigated in rat Achilles tendon models and tendon fibroblast cultures. Published work includes tendon-cell growth and growth-hormone-receptor expression as experimental endpoints. This evidence supports preclinical research context and does not establish a human application for the mixture.
TB-500 identity and literature matching
A primary analytical study identified an N-acetylated thymosin beta-4 fragment, Ac-LKKTETQ, in the TB-500 material it examined. That finding does not establish the sequence of this catalog component. Product-specific identity data are needed before assigning fragment-specific or full-length thymosin beta-4 literature to BBG50; those substances are not interchangeable.
How BBG50 differs from GLOW50
BBG50 contains GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg per vial. GLOW50 contains GHK-Cu 35 mg, BPC-157 5 mg and TB-500 10 mg per vial. Their labeled totals are 70 mg and 50 mg, respectively. Different compositions require independent interpretation; ingredient studies do not establish blend equivalence or synergy.
Frequently Asked Questions
Why does BBG50 total 70 mg?
BBG50 is the SKU name. Its three labeled components add up to 70 mg per vial: BPC-157 10 mg, GHK-Cu 50 mg and TB-500 10 mg.
Is BBG50 the same formulation as GLOW50?
No. BBG50 has 50 mg GHK-Cu and 10 mg BPC-157 per vial; GLOW50 has 35 mg and 5 mg, respectively. Both list 10 mg TB-500 per vial.
Can full-length thymosin beta-4 studies be treated as TB-500 evidence?
Only after confirming that the tested substance matches the supplied component. The TB-500 name alone does not establish sequence or equivalence to full-length thymosin beta-4.
Has this exact combination been validated by the references?
No. The references provide ingredient and analytical research context, not validation of BBG50 synergy or clinical use. This product is for laboratory research only.
Learn more
Read research overviews, COA verification guides, and reconstitution notes in our Knowledge Hub.